Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RTSNBullishCorporate Developmentsnews

High materiality7/10

Retension IPO upsized; RTSN funds RTN-001 toward Phase 3 hypertension trials

Oct 8, 2026, 9:41 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

IPO proceeds plus a clear path to Phase 3 can improve cash runway and clinical momentum; however, dilution and execution risk around trial results remain factors.

AI summary

What happened, with direct paths to the underlying reporting

Retension priced an upsized IPO of 3.75 million shares at $12 each, aiming to raise roughly $45 million with a 30-day option for 562,500 additional shares. RTSN is set to begin trading on Nasdaq as RTSN around October 9, 2026, with an expected close around October 13. Net proceeds will advance RTN-001 through Phase 2b and toward a planned Phase 3 for uncontrolled hypertension, leveraging an exclusive Sanofi license.

Upsized IPO priced at $12; 3.75 million shares.
Gross proceeds expected about $45 million; 30-day option for 562,500.
Trading on Nasdaq Capital Market as RTSN; listing around Oct 9.
Proceeds to fund RTN-001 Phase 2b, prep for Phase 3.
RTN-001 is a PDE5 inhibitor licensed from Sanofi; Phase 2b ongoing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.